The immune system’s surveillance of abnormal cells is one of the reasons most people never develop lymphoma. Drugs that suppress or redirect that surveillance have, in several instances, been associated with increased lymphoma risk — and with litigation over whether patients were adequately warned. Dupixent’s mechanism is different, but the litigation pattern is familiar.
Three precedents
TNF blockers (Humira, Remicade, Enbrel). Reports of lymphoma, including a rare and fatal hepatosplenic T-cell lymphoma in young patients, led to boxed warnings in 2009. Lawsuits followed; most resolved individually.
JAK inhibitors (Xeljanz, Rinvoq, Olumiant). A post-marketing safety trial found elevated cancer and cardiovascular risk. The FDA required boxed warnings in 2021. Litigation over pre-warning use continues.
Elidel and Protopic. Topical calcineurin inhibitors for eczema received boxed warnings for lymphoma in 2006 after case reports — a precedent squarely in the eczema-treatment space.
In each of these, the regulatory record shows the same sequence: adverse event reports, published case series, manufacturer resistance, then a label change. The Dupixent cases are being filed at the point in that sequence where the FDA is still evaluating.
Direct2Attorney · Litigation ContextHow Dupixent differs
Mechanism
Targeted, not broadly suppressive- Blocks IL-4 and IL-13 signaling only
- Does not suppress overall immune function the way TNF blockers do
- Generally regarded as having a favorable safety profile
- Makes causation arguments more specific to CTCL biology
The CTCL connection
Disease-specific- IL-13 signaling is involved in the CTCL tumor environment
- Blocking it may shift the balance toward malignant T cells
- Clinical overlap with eczema drives the masking theory
- Signal is concentrated in one rare cancer, not lymphoma generally
What the precedents suggest
Label changes tend to follow rather than precede litigation, and when they arrive they strengthen failure-to-warn claims by confirming the risk was real. The absolute rarity of the outcome has not prevented recovery in past cases; what matters is whether the manufacturer knew of the signal and what it did. Discovery into Sanofi and Regeneron’s adverse event handling will be the center of MDL 3180.
What it means for claim value
Prior biologic litigation has valued claims by disease stage, treatment intensity, and outcome. Advanced CTCL, systemic therapy, and death sit at the top. Early-stage disease controlled with skin-directed treatment sits lower but has still been compensated. Delayed diagnosis attributable to the drug is a distinct damages element.
What this means if you're considering a claim
The Dupixent litigation is following a well-worn path. If you used the drug and were diagnosed with CTCL or a related T-cell lymphoma, a free review can place your case in that context and connect you with a participating firm in the MDL.
Want your case evaluated in light of the precedents?
Free, confidential review by a participating firm.
Common Questions
Many resolved through confidential individual settlements after label changes. Outcomes varied with the strength of the causation evidence.
No. As of September 2026 the FDA is evaluating the CTCL signal. A boxed warning would be a significant development.
That is a causation question for experts. Mention all immune-modulating drugs during the review.
Several years from first filings to resolution was typical.
No. Direct2Attorney’s review is free, and participating law firms typically work on contingency, meaning fees are generally paid only if there is a recovery. Confirm fee terms in writing with the firm.
